Detalle Publicación

Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease

Autores: Lahuerta, J. J. (Autor de correspondencia); Jimenez-Ubieto, A. ; Paiva, Bruno; Martinez-Lopez, J.; Gonzalez-Medina, J. ; Lopez-Anglada, L. ; Cedena, M. T. ; Puig, N.; Oriol, A.; Blanchard, M. J.; Rios, R.; Martin, J.; Martinez, R.; Sureda, A.; Hernandez, M. T.; de la Rubia, J.; Krsnik, I.; Cabanas, V.; Palomera, L.; Bargay, J.; Mateos, M. V.; Rosinol, L.; San Miguel Izquierdo, Jesús; Blade, J.
Título de la revista: BLOOD
ISSN: 0006-4971
Volumen: 133
Número: 25
Páginas: 2664 - 2668
Fecha de publicación: 2019
Response criteria for multiple myeloma (MM) require monoclonal protein (M-protein)-negative status on both serum immunofixation electrophoresis (sIFE) and urine (uIFE) immunofixation electrophoresis for classification of complete response (CR). However, uIFE is not always performed for sIFE-negative patients. We analyzed M-protein evaluations from 384 MM patients (excluding those with light-chain-only disease) treated in the GEM2012MENOS65 (NCT01916252) trial to determine the uIFE-positive rate in patients who became sIFE-negative posttreatment and evaluate rates of minimal residual disease (MRD)-negative status and progression-free survival (PFS) among patients achieving CR, CR but without uIFE available (uncertain CR; uCR), or very good partial response (VGPR). Among 107 patients with M-protein exclusively in serum at diagnosis who became sIFE-negative posttreatment and who had uIFE available, the uIFE-positive rate was 0%. Among 161 patients with M-protein in both serumand urine at diagnosis who became sIFE-negative posttreatment, 3 (1.8%) were uIFE positive. Among patients achieving CR vs uCR, there were no significant differences in postconsolidation MRD-negative (< 10(-6); 76% vs 75%; P = .9) and 2-year PFS (85% vs 88%; P = .4) rates; rates were significantly lower among patients achieving VGPR. Our results suggest that uIFE is not necessary for defining CR in MM patients other than those with light-chain-only disease.